solanezumab

Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
BioSpace
Thu, 03/9/23 - 11:46 am
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Lilly and Roche's antibodies fail late-phase Alzheimer's test
Fierce Biotech
Mon, 02/10/20 - 10:17 am
Eli Lilly
Roche
Alzheimer's disease
clinical trials
solanezumab
gantenerumab
Preventive Alzheimer's trial data due within weeks, Lilly says
BioPharma Dive
Thu, 01/30/20 - 09:14 pm
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s
Endpoints
Thu, 01/25/18 - 09:31 am
Eli Lilly
clinical trials
Alzheimer's disease
solanezumab
Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?
Xconomy
Wed, 06/21/17 - 09:46 am
Alzheimer's disease
anti-amyloid
solanezumab
Eli Lilly
Biogen
aducanumab
RVT-101
Over And Out For Solanezumab, While Biogen Takes The Spotlight
Seeking Alpha
Tue, 12/13/16 - 10:22 am
solanezumab
Biogen
Eli Lilly
aducanumab
Alzheimer's disease
Eli Lilly conducts an autopsy of an Alzheimer’s megaflop
Endpoints
Thu, 12/8/16 - 11:12 pm
Eli Lilly
Alzheimer's disease
solanezumab
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
Why Eli Lilly Shares Lost 8% in November
Motley Fool
Sun, 12/4/16 - 12:23 pm
Eli Lilly
clinical trials
solanezumab
Alzheimer's disease
In Lechleiter’s final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion
Endpoints
Wed, 11/30/16 - 10:10 am
Eli Lilly
John Lechleiter
layoffs
solanezumab
Alzheimer's disease
Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies
TheStreet.com
Tue, 11/29/16 - 09:49 am
Eli Lilly
Alzheimer's disease
solanezumab
AC Immune
Axovant
Biogen
Merck
Roche
Does Lilly's Alzheimer's Fail Hurt Biogen?
Investopedia
Fri, 11/25/16 - 09:22 am
Biogen
Eli Lilly
Alzheimer's disease
solanezumab
Lilly's sola failure throws Alzheimer's theory into doubt
BioPharma Dive
Fri, 11/25/16 - 09:21 am
Eli Lilly
solanezumab
Alzheimer's disease
Biogen loses $4 billion in market cap on Eli Lilly Azheimer's news
Bizjournals.com
Wed, 11/23/16 - 12:05 pm
Biogen
Eli Lilly
Alzheimer's disease
solanezumab
Eli Lilly (LLY) CEO Lechleiter 'Disappointed,' after Alzheimer's Drug Fails
TheStreet.com
Wed, 11/23/16 - 10:29 am
Eli Lilly
Alzheimer's disease
clinical trials
solanezumab
John Lechleiter
[video] Eli Lilly's Alzheimer Drug Fails Final-Stage Trial
Bloomberg
Wed, 11/23/16 - 10:27 am
Eli Lilly
Alzheimer's disease
clinical trials
solanezumab
Solanezumab And The History Of The Future Of Treating Alzheimer's Disease
Forbes
Fri, 11/11/16 - 09:48 am
Alzheimer's disease
solanezumab
Eli Lilly
In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success
Yahoo/Benzinga
Mon, 10/3/16 - 09:45 pm
Eli Lilly
Alzheimer's disease
solanezumab
Eli Lilly: This is Gonna Be Good
Barron's
Tue, 09/27/16 - 10:07 pm
Eli Lilly
solanezumab
Alzheimer's disease
10 Must-Know Biotech Stock Events to Close Out 2016
TheStreet.com
Fri, 09/9/16 - 09:04 pm
biotech
Eli Lilly
solanezumab
Biogen
aducanumab
Kite Pharma
KTE-C19
Bluebird Bio
LentiGlobin
Sarepta Therapeutics
eteplirsen
Ophthotech
Fovista
Bristol-Myers Squibb
Opdvio
Acadia
Nuplazid
Celgene
GED-301
Gilead Sciences
M&A

Pages